Longtime Sage Therapeutics executive Jeff Jonas is leaving the biotech company to launch a biotech incubator with global investment giant CBC Group.
Sage announced this week that Jonas would leave the company to join a private equity firm. He has been part of the C-suite at Sage Therapeutics since 2013. He helped the company go public, build a pipeline of new antidepressants and other psychiatric medications, and sign a $1.5 billion deal with Biogen.
Jonas’ next step came to light on Thursday, when CBC announced that it has hired Jonas to lead a new biotech incubator called ABiox-X. CBC is funneling $150 million into the incubator, having closed a $1.67 billion health care fund in April.
This article is exclusive to STAT+ subscribers
Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.
Already have an account? Log in
Already have an account? Log in
To submit a correction request, please visit our Contact Us page.
STAT encourages you to share your voice. We welcome your commentary, criticism, and expertise on our subscriber-only platform, STAT+ Connect